STAT Plus: Biotech enters an era of ‘platform’ dominance
There was a time, back in biotech’s leaner years, when any company hoping to raise even a dollar needed a clear path to get a single drug through clinical trials.
Now, in today’s gilded age of VC largesse, companies can raise nine-figure funding rounds without so much as deciding on a discrete disease area.
Continue to STAT Plus to read the full story…
Read Original Article: STAT Plus: Biotech enters an era of ‘platform’ dominance »
